Global Azilsartan Medoxomil API Market Growth 2025-2031

The global Azilsartan Medoxomil API market size is predicted to grow from US$ 21.6 million in 2025 to US$ 66.7 million in 2031; it is expected to grow at a CAGR of 20.7% from 2025 to 2031.

Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase.

Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.

LP Information, Inc. (LPI) ' newest research report, the “Azilsartan Medoxomil API Industry Forecast” looks at past sales and reviews total world Azilsartan Medoxomil API sales in 2024, providing a comprehensive analysis by region and market sector of projected Azilsartan Medoxomil API sales for 2025 through 2031. With Azilsartan Medoxomil API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Azilsartan Medoxomil API industry.

This Insight Report provides a comprehensive analysis of the global Azilsartan Medoxomil API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Azilsartan Medoxomil API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Azilsartan Medoxomil API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Azilsartan Medoxomil API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Azilsartan Medoxomil API.

This report presents a comprehensive overview, market shares, and growth opportunities of Azilsartan Medoxomil API market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
0.99
Others

Segmentation by Application:
20 mg Tablets
40 mg Tablets
80 mg Tablets

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co

Key Questions Addressed in this Report

What is the 10-year outlook for the global Azilsartan Medoxomil API market?

What factors are driving Azilsartan Medoxomil API market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Azilsartan Medoxomil API market opportunities vary by end market size?

How does Azilsartan Medoxomil API break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.